Introduction Histogen is a company that specializes in regenerative medicine, using a unique biological platform to replace and regenerate damaged tissues within the body. Their cutting-edge technology involves the use of cell-conditioned media and extracellular matrix materials created by multipotent cells under hypoxic conditions. This allows for the development of therapeutic products that can address significant global markets with unmet medical needs. Founded in 2007 by Dr. Gail Naughton, Histogen is based in San Diego, California. |
Disease Domain | Count |
---|---|
Infectious Diseases | 2 |
Endocrinology and Metabolic Disease | 1 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 4 |
Cell therapy | 1 |
Stem cell therapy | 1 |
Biological products | 1 |
Top 5 Target | Count |
---|---|
caspase 1(Caspase-1) | 2 |
FGFRs(Fibroblast growth factor receptors) | 1 |
CASP(Caspase) | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism FGFRs stimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism caspase inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseIND Approval |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date15 Nov 2021 |
Sponsor / Collaborator Histogen, Inc. [+1] |
Start Date11 Mar 2021 |
Sponsor / Collaborator |
Start Date26 May 2020 |
Sponsor / Collaborator |